Navigation Links
Ambry Genetics Research Highlights Need for Expanded Genetic Testing Payer Coverage for Patients At-Risk for Hereditary Breast and Ovarian Cancer
Date:5/2/2019

Researchers from Ambry Genetics (Ambry), a leading clinical genetics testing company, will present results documenting discrepancies between U.S. insurer policies for genetic testing and the 2019 National Comprehensive Cancer Network (NCCN) medical management guidelines for patients at risk for hereditary breast and ovarian cancer (HBOC).

Jill S. Dolinsky, director of clinical affairs at Ambry Genetics, explained why this research is significant: “Multigene panel testing (MGPT) is now the preferred method for clinicians testing for HBOC because it enables adherence to the latest NCCN guidelines, which now include medical management recommendations for people with mutations in 16 different genes. Unfortunately, adoption of MGPT has outpaced insurance coverage. We felt there was a need to quantify how current insurance coverage guidelines impact patient access to testing and subsequent clinical management.”

Ambry assessed MGPT orders for patients insured by three major insurance carriers. Results revealed significant disparities among insurers as to the number and type of the 16 genes outlined in NCCN management guidelines covered. On a patient level, overlaying these results with NCCN management guidelines indicate that 25.6% of patients who should consider breast MRI screening and 10.5% of patients who should consider risk-reducing surgery for ovarian cancer would be missed if testing was limited to the genes covered under the insurance medical policies.

“On the patient level, the impact of these discrepancies is serious,” said Rob Guigley, vice president of market access at Ambry Genetics. “In line with a limited number of the nation’s largest insurers, the data highlight the urgent need for payers to update their medical policy to be in step with the NCCN guidelines to ensure at-risk patients have access to HBOC genetic testing and can benefit from early detection and a potential reduction of their cancer risk."

Presentation #581999 is being presented on Friday, May 3rd, 2019, 6:00-7:30 PM at the ASBrS Annual Meeting.

About Ambry Genetics
Ambry Genetics is a leader in clinical diagnostic and software solutions, combining both to offer comprehensive and high-quality genetic testing. As part of the Konica Minolta family, Ambry Genetics is responsibly applying new technologies to the molecular diagnostics market to bring about precision medicine. With over 20 years of experience, Ambry Genetics has longstanding expertise in clinical genetic testing. For more information about Ambry Genetics, visit http://www.ambrygen.com.

Press Contact:
June Fujimoto
press(at)ambrygen.com
949-301-2454

Read the full story at https://www.prweb.com/releases/ambry_genetics_research_highlights_need_for_expanded_genetic_testing_payer_coverage_for_patients_at_risk_for_hereditary_breast_and_ovarian_cancer/prweb16280632.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Ambry Genetics Launches New Neurodevelopmental Genetic Testing Panel
2. Ambry Genetics to Present Seven Abstracts at Upcoming ACMG Annual Clinical Genetics Meeting
3. Ambry Genetics Shares New Data on Genetic Causes for Neurodevelopmental Conditions, Further Adding to Growing Body of Evidence in Neurology
4. JAMA Oncology Publishes Ambry’s Results Detailing Genes Associated with Hereditary Breast and Ovarian Cancer
5. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
6. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
7. Todays Technical View: Elan Corp., Amarin, Seattle Genetics, and Cubist Pharma
8. Signal Genetics LLC Announces Update to MyPRS™ Gene Expression Profiling Assay for Multiple Myeloma
9. Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
10. Cytogenetics - Technologies, Markets and Companies - 2013
11. Population Genetics Assigns Asymmetric Adaptor Library Construction Patent To New England Biolabs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... ... Personalized Stem Cells Inc. (PSC) , has announced that their GMP facility for ... and Drug Branch for manufacturing. This is an important milestone for VetStem ...
(Date:6/6/2019)... ... June 05, 2019 , ... WCCT Global, Inc ., ... industries, announced today that they will be receiving 3 awards at the 2019 CRO ... received 2 awards in the categories of overall Quality and Compatibility (Access to desired ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... applications from the USPTO providing proprietary interest to our methodology, processes, and ... DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep ...
(Date:5/31/2019)... BEACH, Calif. (PRWEB) , ... May 30, 2019 ... ... future of neurotoxins, is pleased to announce the strategic acquisition of Metabiologics, Inc., ... research. The acquisition provides Object exclusive ownership and commercialization rights to a full ...
Breaking Biology Technology:
(Date:6/4/2019)... ... 2019 , ... Lajollacooks4u is delighted to announce it has been named as ... is given only to businesses that have achieved consistently outstanding traveler reviews on TripAdvisor, ... , To qualify for the Certificate of Excellence –- an award that only 10 ...
(Date:5/31/2019)... ... May 30, 2019 , ... ... company, and Mayo Clinic, have documented significant differences in the prevalence of hereditary ... ethnic populations compared to non-Hispanic White women. Results will be presented at the ...
(Date:5/26/2019)... (PRWEB) , ... May 24, 2019 , ... Zolgensma (Novartis, ... as AVXS-101, was approved for clinical use in the United States by the Food ... virally-delivered gene therapy approved to treat inherited genetic disorders in the United States and ...
Breaking Biology News(10 mins):